Literature DB >> 27418577

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Andre C Kalil1, Mark L Metersky2, Michael Klompas3, John Muscedere4, Daniel A Sweeney5, Lucy B Palmer6, Lena M Napolitano7, Naomi P O'Grady8, John G Bartlett9, Jordi Carratalà10, Ali A El Solh11, Santiago Ewig12, Paul D Fey13, Thomas M File14, Marcos I Restrepo15, Jason A Roberts16, Grant W Waterer17, Peggy Cruse18, Shandra L Knight18, Jan L Brozek19.   

Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia. The panel's recommendations for the diagnosis and treatment of HAP and VAP are based upon evidence derived from topic-specific systematic literature reviews.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27418577      PMCID: PMC4981759          DOI: 10.1093/cid/ciw353

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  346 in total

Review 1.  Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia.

Authors:  John G Muscedere; Andrew Day; Daren K Heyland
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

2.  Economic impact of ventilator-associated pneumonia in a large matched cohort.

Authors:  Marin H Kollef; Cindy W Hamilton; Frank R Ernst
Journal:  Infect Control Hosp Epidemiol       Date:  2012-01-17       Impact factor: 3.254

3.  Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor.

Authors:  Keith M Ramsey; Mark A Mazer
Journal:  Crit Care Med       Date:  2010-01       Impact factor: 7.598

4.  Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia.

Authors:  R Saginur; G Garber; G Darling; S Shafran; W Cameron; G Jones; F Auclair
Journal:  Can J Infect Dis       Date:  1997-03

5.  Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients.

Authors:  Mariano Esperatti; Miquel Ferrer; Anna Theessen; Adamantia Liapikou; Mauricio Valencia; Lina Maria Saucedo; Elisabeth Zavala; Tobias Welte; Antoni Torres
Journal:  Am J Respir Crit Care Med       Date:  2010-08-06       Impact factor: 21.405

6.  Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes.

Authors:  Chris M Parker; Jim Kutsogiannis; John Muscedere; Deborah Cook; Peter Dodek; Andrew G Day; Daren K Heyland
Journal:  J Crit Care       Date:  2008-03       Impact factor: 3.425

7.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

8.  Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU.

Authors:  Mariano Esperatti; Miquel Ferrer; Valeria Giunta; Otavio Tavares Ranzani; Lina Maria Saucedo; Gianluigi Li Bassi; Francesco Blasi; Jordi Rello; Michael S Niederman; Antoni Torres
Journal:  Crit Care Med       Date:  2013-09       Impact factor: 7.598

9.  Procalcitonin increase after endotoxin injection in normal subjects.

Authors:  P Dandona; D Nix; M F Wilson; A Aljada; J Love; M Assicot; C Bohuon
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

Review 10.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

View more
  672 in total

1.  Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.

Authors:  Jien-Wei Liu; Yen-Hsu Chen; Wen-Sen Lee; Jung-Chung Lin; Ching-Tai Huang; Hsi-Hsun Lin; Yung-Ching Liu; Yin-Ching Chuang; Hung-Jen Tang; Yao-Shen Chen; Wen-Chien Ko; Min-Chi Lu; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Authors:  Ana Motos; Joseph L Kuti; Gianluigi Li Bassi; Antoni Torres; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.

Authors:  Besu F Teshome; Scott Martin Vouri; Nicholas Hampton; Marin H Kollef; Scott T Micek
Journal:  Pharmacotherapy       Date:  2019-01-07       Impact factor: 4.705

Review 4.  [Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].

Authors:  C Lanckohr; H Bracht
Journal:  Anaesthesist       Date:  2018-01       Impact factor: 1.041

5.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

6.  Evaluation of a pharmacy-driven methicillin-resistant Staphylococcus aureus surveillance protocol in pneumonia.

Authors:  Sarah Dunaway; Kara W Orwig; Zachary Q Arbogast; Zachary L Myers; James A Sizemore; Stephanie E Giancola
Journal:  Int J Clin Pharm       Date:  2018-05-02

7.  Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study.

Authors:  Mohammed J Al-Jaghbeer; Julie Ann Justo; William Owens; Joseph Kohn; P Brandon Bookstaver; Jennifer Hucks; Majdi N Al-Hasan
Journal:  Infection       Date:  2018-05-11       Impact factor: 3.553

8.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

Review 9.  Intravenous Minocycline: A Review in Acinetobacter Infections.

Authors:  Sarah L Greig; Lesley J Scott
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

10.  Trimetoprim-sulfametoxazole in ventilator-associated pneumonia: a cohort study.

Authors:  Alessio Strazzulla; Maria Concetta Postorino; Anastasia Purcarea; Catherine Chakvetadze; Astrid de Farcy de Pontfarcy; Gianpiero Tebano; Aurelia Pitsch; Lyvan Vong; Sebastien Jochmans; Christophe Vinsonneau; Mehran Monchi; Sylvain Diamantis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.